Emergex Vaccines has secured a state-of-the-art-research and development (R&D) facility at Milton Park, Oxfordshire in the UK.   In addition, the company has appointed Phillip Williams as chief scientific officer, who will lead the company’s R&D operations on site. A nanotechnology expert, Dr. Williams has extensive experience in the field of gold nanoparticle development and has been involved in the production and validation of the world’s first up-scaling methodologies for nanoparticle...